Zobrazeno 1 - 10
of 237
pro vyhledávání: '"Alberto J Montero"'
Publikováno v:
Therapeutics and Clinical Risk Management, Vol 2008, Iss Issue 6, Pp 1157-1164 (2008)
Vinay Gudena, Alberto J Montero, Stefan GlückDivision of Hematology/Oncology, Braman Family Breast Cancer Institute, UMSylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USAAbstract: Incremental advance
Externí odkaz:
https://doaj.org/article/dca47d3f980848be98650345dfcc29b8
Autor:
Samuel A. Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J. Montero, Corey Lipchik, Melanie Finnigan, Rachel C. Jankowitz, Mohamad A. Salkeni, Sai K. Maley, Shannon L. Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J. Nagy, Carmen J. Allegra, Kelly Vehec, Norman Wolmark, Peter C. Lucas, Ashok Srinivasan, Katherine L. Pogue-Geile
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-13 (2024)
Abstract Background We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA had deeper and more dura
Externí odkaz:
https://doaj.org/article/c30874be81f04b78be67858f937fdb82
Autor:
Nickolas Stabellini, Jennifer Cullen, Marcio S. Bittencourt, Justin X. Moore, Arnethea Sutton, Priyanshu Nain, Nelson Hamerschlak, Neal L. Weintraub, Susan Dent, Meng‐Han Tsai, Amitava Banerjee, Arjun K Ghosh, Diego Sadler, Steven S. Coughlin, Ana Barac, John Shanahan, Alberto J. Montero, Avirup Guha
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 14 (2024)
Background Cardiovascular disease and cancer share a common risk factor: chronic stress/allostatic load (AL). A 1‐point increase in AL is linked to up to a 30% higher risk of major cardiac events (MACE) in patients with prostate cancer. However, AL
Externí odkaz:
https://doaj.org/article/7618f7b4375e4dc3988926621ce3be61
Publikováno v:
Cancer Medicine, Vol 12, Iss 19, Pp 19607-19616 (2023)
Abstract Background Validation studies of the 21‐gene recurrence score (RS) previously demonstrated that adjuvant chemotherapy plus endocrine therapy (CET) was associated with a significant survival benefit in women with node negative breast cancer
Externí odkaz:
https://doaj.org/article/1e231321697746d6ad6543a1abb9eae6
Autor:
Mohammadhadi Khorrami, Vidya Sakar Viswanathan, Priyanka Reddy, Nathaniel Braman, Siddharth Kunte, Amit Gupta, Jame Abraham, Alberto J. Montero, Anant Madabhushi
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract The combination of Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) is the standard of care for hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer
Externí odkaz:
https://doaj.org/article/f997f48cfd63439786061cd76e2b42ae
Autor:
Demitrios Dedousis, Annie L. Zhang, Anastasia N. Vassiliou, Shufen Cao, Deepthi Yammani, Ravi K. Kyasaram, John P. Shanahan, Melissa C. Keinath, Melinda L. Hsu, Pingfu Fu, Afshin Dowlati, Alberto J. Montero
Publikováno v:
Cancer Medicine, Vol 12, Iss 12, Pp 13086-13099 (2023)
Abstract Background Patients with certain autoimmune conditions are at a reduced risk of developing breast cancer compared to the general population. Despite this, little is known about outcomes in patients with breast cancer who have a concurrent au
Externí odkaz:
https://doaj.org/article/48f597776f8d4666879c67d21dc5d57b
Autor:
Nickolas Stabellini, Benjamin Tomlinson, Jennifer Cullen, John Shanahan, Kristin Waite, Alberto J. Montero, Jill S. Barnholtz‐Sloan, Nelson Hamerschlak
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 6711-6721 (2023)
Abstract Background There is a male predominance of acute myeloid leukemia (AML) incidence, but survival data are conflicting. The objective of this study is to carry out a comprehensive analysis of sex differences in AML, and to investigate the impa
Externí odkaz:
https://doaj.org/article/abeec90b78524f8d919704675ccfbdd9
Autor:
Samuel A. Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J. Montero, Corey Lipchik, Melanie Finnigan, Rachel C. Jankowitz, Mohamad A. Salkeni, Sai K. Maley, Shannon L. Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J. Nagy, Carmen J. Allegra, Kelly Vehec, Norman Wolmark, Peter C. Lucas, Ashok Srinivasan, Katherine L. Pogue-Geile
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/4cc93b26e3c04e74a206892c9a22fe0a
Autor:
Nickolas Stabellini, Jennifer Cullen, Lifen Cao, John Shanahan, Nelson Hamerschlak, Kristin Waite, Jill S. Barnholtz-Sloan, Alberto J. Montero
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract The main objective of this work was to perform a comprehensive analysis and provide a race-stratified epidemiological report accounting for differences in treatment patterns and treatment related adverse events in Non-Hispanic women with bre
Externí odkaz:
https://doaj.org/article/5f27e2b0610c4b2dad3725ff678ed6df
Autor:
Nickolas Stabellini, Lifen Cao, Christopher W. Towe, Xun Luo, Amanda L. Amin, Alberto J. Montero
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe RxPONDER trial found that among breast cancer patients with estrogen receptor positive (ER+) breast cancer, 1-3 positive axillary nodes, and a recurrence score of ≤25, only pre-menopausal women benefitted from adjuvant chemoendocrine
Externí odkaz:
https://doaj.org/article/4013ba368b0840f3b7b623714ea19cec